Literature DB >> 6087658

Tumor markers and neurological signs in asbestosis patients.

J Järvisalo, J Juntunen, M S Huuskonen, H Kivistö, A Aitio.   

Abstract

Ninety asbestosis patients were examined clinically with special emphasis on the function of the peripheral and the central nervous system. Serum specimens were analyzed for carcinoembryonic antigen(s) (CEA), ferritin, and beta 2-microglobulin (beta 2m) content. The patients were classified into four subgroups: (1) those with peripheral neuropathy, (2) those with involvement of central nervous system, (3) those with both types of neurological signs, and (4) those with normal neurological status. The levels of serum CEA, ferritin, and beta 2m were elevated in all four subgroups. No statistically significant differences were found between the groups in the prevalence of elevated values of the three tumor markers (equal or above the following limits: CEA, 5 micrograms/liter; ferritin, 400 micrograms/liter, and beta 2m, 3 mg/liter). The patients currently smoking had a higher level of serum CEA than nonsmokers or exsmokers, but the differences were not statistically significant. In the subgroup that comprised those asbestosis patients in whom the disease could be considered progressive according to the ILO 1980 classification of the chest radiographs, the mean level of CEA in serum was higher than that of the patient group without such progression of the disease (p less than 0.05, Student's t test). Although the prevalence of abnormal neurological signs was high in these asbestosis patients, no obvious correlation was found between the neurological findings and the tumor markers studied.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087658     DOI: 10.1002/ajim.4700060210

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  1 in total

1.  Neurological signs in relation to cancer in patients with asbestosis.

Authors:  J Juntunen; P Oksa; E Pukkala; P Laippala
Journal:  Occup Environ Med       Date:  1997-10       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.